| Autor: |
Néčová, S, Mason, SL, North, SM |
| Předmět: |
|
| Zdroj: |
Australian Veterinary Journal; May2021, Vol. 99 Issue 5, p146-151, 6p |
| Abstrakt: |
Objectives: The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Animals: Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. Procedures: Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re‐staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease‐free interval (DFI) and median survival time (MST) were calculated using Kaplan–Meier method. Results: Twenty‐one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow‐up period of the whole study population was 1112 days (358–2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One‐year and 2‐year survivals were 95.2% and 90.5%, respectively. Conclusions and clinical relevance: This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text